Published On: Mon, Jun 19th, 2017

GenMark Diagnostics, Inc. (GNMK) Analyst Coverage


A number of investment brokers have recently updated their price targets on shares of GenMark Diagnostics, Inc. (GNMK).

Most recent broker ratings

06/12/2017 – GenMark Diagnostics, Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 17 price target on the stock.

09/16/2016 – GenMark Diagnostics, Inc. was upgraded to “outperform” by analysts at Cowen. They now have a USD 17 price target on the stock.

02/10/2016 – GenMark Diagnostics, Inc. had its “buy” rating reiterated by analysts at BTIG Research. They now have a USD 9 price target on the stock.

10/28/2015 – GenMark Diagnostics, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 8 price target on the stock.

01/20/2015 – GenMark Diagnostics, Inc. had its “outperform” rating reiterated by analysts at Raymond James. They now have a USD 15.5 price target on the stock.

05/07/2014 – GenMark Diagnostics, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 16 price target on the stock.

10/14/2013 – GenMark Diagnostics, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 14 price target on the stock.

The share price of GenMark Diagnostics, Inc. (GNMK) was down -0.08% during the last day of trading, with a day high of 12.20. 365100 shares were traded during the last session.

The stock’s 50 day moving average is 12.89 and its 200 day moving average is 12.31. The stock’s market capitalization is 565.51M. GenMark Diagnostics, Inc. has a 52-week low of 7.82 and a 52-week high of 13.67.

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.